Import and sourcing
APIs, excipients and finished products from manufacturers we already work with, brought into Iran with the certificates and stability data the authority expects.
Hanpars imports active ingredients, finished medicines, excipients and nutrition ingredients, and registers them with the IFDA. Based in Tehran, with suppliers in Türkiye, China, India and Europe.
A supply agreement is only useful once the product is approved and on the shelf, so sourcing, registration and project coordination sit with the same people.
APIs, excipients and finished products from manufacturers we already work with, brought into Iran with the certificates and stability data the authority expects.
Strategy before the first study. Evidence built into the dossier. Approval secured. Authorisation maintained through every change.
For finished dosage-form projects we coordinate development and manufacturing partners, with responsibilities written down at the start. We run the project; partners run the plant.
Contrast media, anaesthetics, antibiotics, hormones and biologics from GMP-certified manufacturers, distributed nationally through Pakhsh Razi, Darougostar Tooba and Dey Darou Omid. Hanpars is a contracted supplier to the national Strategic Medicine Reserve.
Status as of October 2026; confirm availability when you enquire.
Hanpars is the marketing authorisation holder for the medicines it imports: the dossier, the IRC licence and pharmacovigilance are handled in-house. We source, register and coordinate; manufacturers manufacture, and the authority decides. Saying precisely who does what is how we keep projects moving.
Haniya Parsan Darou Co. · 3rd floor, No. 326, Zafar Street, Africa Boulevard, TehranOffice hours 09:00–17:00 · +98 21 8888 3325 About HanparsA product name and a destination are enough to start.
The product, the strength or grade, the quantity and where it is going.
Who can supply it, what the market will require, and what is realistic for timing.
Who does what, in writing, with one contact at Hanpars accountable for it.
Recon: FDA approves GSK hepatitis B drug; EQT to buy molecular testing firm Qiagen for $10.8B RAPS
Read at raps.orgFDA Grants Ultomiris Accelerated Approval in the U.S. | PharmExec Pharmaceutical Executive
Read at pharmexec.comProBio Successfully Completes NMPA Pre-Approval Inspection for Biologics Manufacturing Facility in Nanjing, China PR Newswire
Read at prnewswire.comSend the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.